Comparison of Oral Ibuprofen with Oral Indomethacin for PDA Closure in Indian Preterm Neonates: A Randomized Controlled Trial

详细信息    查看全文

• 作者：Sanju Yadav (1)
  Sheetal Agarwal (2)
  Arti Maria (3)
  Ajay Dudeja (4)
  N. K. Dubey (1)
  Puneet Anand (2)
  Dinesh Kumar Yadav (2) (5)
  
• 关键词：Oral ibuprofen ; Indomethacin ; PDA closure ; Preterm
• 刊名：Pediatric Cardiology
• 出版年：2014
• 出版时间：June 2014
• 年：2014
• 卷：35
• 期：5
• 页码：824-830
• 全文大小：
• 参考文献：1. Aly H, Lofty W, Badrawi N et al (2007) Oral ibuprofen and ductus arteriosus in premature infants: a randomized pilot study. Am J Perinatol 24:267-70 k" title="It opens in new window">CrossRef
  2. Barzilay B, Youngster I, Batash D et al (2012) Pharmacokinetics of oral ibuprofen for patent ductus arteriosus closure in preterm infants. Arch Dis Child Fetal Neonatal Ed 97(2):F116–F119 k" title="It opens in new window">CrossRef
  3. Bernstein D (1999) Congenital heart disease. In: Behrman ER, Kliegman RM, Jenson HB (eds) Nelson textbook of pediatrics, 16th edn. Saunders Company, Philadelphia, pp 1362-413
  4. Cherif A, Khrouf N, Jabnoun S et al (2008) Randomized pilot study comparing oral ibuprofen with intravenous ibuprofen in very low birth weight infants with patent ductus arteriosus. Pediatrics 122:e1256–e1261 k" title="It opens in new window">CrossRef
  5. Chotigeat U, Jirapapa K, Layangkool T (2003) A comparison of oral ibuprofen and intravenous indomethacin for closure of patent ductus arteriosus in preterm infants. J Med Assoc Thai 86(Suppl 3):S563–S569
  6. Clyman RI (1996) Recommendations for the postnatal use of indomethacin: an analysis of four separate treatment strategies. J Pediatr 128:601-07 k" title="It opens in new window">CrossRef
  7. Clyman RI, Chome N (2007) Patent ductus arteriosus: evidence for and against treatment. J Pediatr 150:216-19 k" title="It opens in new window">CrossRef
  8. Fakhraee SH, Badiee Z, Mojtahedzadeh S et al (2007) Comparison of oral ibuprofen an indomethacin therapy for patent ductus arteriosus in preterm infants. Zhongguo Dang Dai Er Ke Za Zhi 9:399-03
  9. Ferencz C, Loffredo CA, Correa-Villasenor A, Wilson PD (1997) Patent arterial duct. I: genetic and environmental risk factors of major cardiovascular malformations. The Baltimore-Washington Infant Study 1981-989. Fuytura Publishing Co., Inc, Armonk, pp 285-99
  10. Heymann MA, Rudolph AM, Silverman NH (1976) Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med 295(10):530-33 k" title="It opens in new window">CrossRef
  11. Hirt D, Van Overmeire B, Treluyer JM et al (2008) An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study. Br J Clin Pharmacol 65:629-36 k" title="It opens in new window">CrossRef
  12. Kumar RK, Yu VYH (1997) Prolonged low-dose indomethacin therapy for patent ductus arteriosus in very low birthweight infants. J Paediatr Child Health 33:38-1 k" title="It opens in new window">CrossRef
  13. Mehta SK, Younoszai A, Pietz J, Achanti BP (2003) Pharmacological closure of the patent ductus arteriosus. Images Paediatr Cardiol 5(1):1-5
  14. Ohlsson A, Walia R, Shah SS (2010) Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev (4):CD003481
  15. Patel J, Marks KA, Roberts I, Azzopardi D, Edwards AD (1995) Ibuprofen treatment of patent ductus arteriosus. Lancet 346:255 k" title="It opens in new window">CrossRef
  16. Patel J, Roberts I, Azzopardi D, Hamilton P, Edwards AD (2000) Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. Pediatr Res 47(1):36-2 k" title="It opens in new window">CrossRef
  17. Pourarian Sh, Pishva N, Madani A, Rastegari M (2008) Comparison of oral ibuprofen and indomethacin on closure of patent ductus arteriosus in preterm infants. East Mediterr Health J 14:360-65
  18. Ravi Kumar BP, Dudala SR, Rao AR (2013) Kuppuswamy’s Socio-Economic Status Scale: a revision of economic parameter for 2012. Int J Res Dev Health 1(1):2-
  19. Richards J, Johnson A, Fox G, Campbell M et al (2009) A second course of ibuprofen is effective in the closure of a clinically significant PDA in ELBW infants. Pediatrics 124(2):e287–e293 k" title="It opens in new window">CrossRef
  20. Sharma PK, Garg SK, Narang A (2003) Pharmacokinetics of oral ibuprofen in premature infants. J Clin Pharmacol 43:968-73 k" title="It opens in new window">CrossRef
  21. Su BH, Watanabe T, Shimizu M, Yanagisawa M (1997) Echocardiographic assessment of patent ductus arteriosus shunt flow pattern in premature infants. Arch Dis Child Fetal Neonatal Ed 77:F36–F40 k" title="It opens in new window">CrossRef
  22. Su BH, Lin HC, Chiu HY, Hsieh HY, Chen HH, Tsai YC (2008) Comparison of ibuprofen and indomethacin for early targeted treatment of patent ductus arteriosus in extremely premature infants a randomized controlled trial. Arch Dis Child Fetal Neonatal Ed 93:F94–F99 k" title="It opens in new window">CrossRef
  23. Supapannachart S, Limrungsikul A, Khowsathit P (2002) Oral ibuprofen and indomethacin for treatment of patent ductus arteriosus in premature infants: a randomized trial at Ramathibodi Hospital. J Med Assoc Thai 85(Suppl 4):S1252–S1258
  24. Treluyer JM, Gueret G, Cheron G, Sonnier M, Cresteil T (1997) Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in vivo/in vitro correlation and inducibility. Pharmacogenetics 7:441-52 k" title="It opens in new window">CrossRef
  25. Van Overmeire B, Follens I, Hartmann S, Creten WL, Van Acker KJ (1997) Treatment of patent ductus arteriosus with ibuprofen. Arch Dis Child Fetal Neonatal Ed 76:F179–F184 k" title="It opens in new window">CrossRef
  26. Van Overmeire B, Smets K, Lecoutere D et al (2000) A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Eng J Med 343:674-81 k" title="It opens in new window">CrossRef
  27. Varvarigou A, Bardin CL, Beharry K et al (1996) Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants. JAMA 275:539-44 k" title="It opens in new window">CrossRef
  28. Weir FJ, Ohlsson A, Myhr TL et al (1999) A patent ductus arteriosus is associated with reduced middle cerebral artery blood flow velocity. Eur J Pediatr 158:484-87 k" title="It opens in new window">CrossRef
  29. Weiss H, Cooper B, Brook M, Schlueter M, Clyman R (1995) Factors determining reopening of the ductus arteriosus after successful clinical closure with indomethacin. J Pediatr 127:466-71 k" title="It opens in new window">CrossRef
  30. Wong AR, Ramli N et al (2010) Closure of the patent ductus arteriosus with ibuprofen and other non-steroidal anti inflammatory medications in neonates. East J Med 15:139-45
  
• 作者单位：Sanju Yadav (1)
  Sheetal Agarwal (2)
  Arti Maria (3)
  Ajay Dudeja (4)
  N. K. Dubey (1)
  Puneet Anand (2)
  Dinesh Kumar Yadav (2) (5)
  
  1. Department of Pediatrics, PGIMER & Associated Dr RML Hospital, New Delhi, India
  2. Division of Pediatric Cardiology, Department of Pediatrics, PGIMER & Associated Dr RML Hospital, New Delhi, India
  3. Division of Neonatalogy, Department of Pediatrics, PGIMER & Associated Dr RML Hospital, New Delhi, India
  4. Department of Pediatrics & Neonatalogy, LHMC & KSCH, New Delhi, India
  5. Abhay Khand- I, H. No 169 Indirapuram, Ghaziabad, Uttar Pradesh, India
  
• ISSN：1432-1971

文摘

Oral ibuprofen is being used as an alternative to indomethacin in medical management of patent ductus arteriosus (PDA), but limited data exist on oral efficacy of these drugs for PDA closure in India. To assess and compare the efficacy of oral ibuprofen and oral indomethacin for PDA closure in preterm Indian neonates, we designed a randomized controlled study on clinically diagnosed and echocardiographically confirmed hemodynamically significant PDA in preterm neonates. Patients were assigned to receive either oral ibuprofen at a dosage of 10, 5, 5?mg/kg every 24?h or three doses of oral indomethacin (0.20-.25?mg/kg every 24?h) starting on the third day of life or when diagnosed. A second course of ibuprofen/indomethacin was given, if PDA failed to close within 48?h after the first course. Patients were monitored for complications like oliguria, bleeding, necrotizing enterocolitis, intraventricular hemorrhage, oxygen dependency, and gastrointestinal side effects. The baseline characteristics were comparable in both groups. Of the 83 children enrolled, 57.8?% received oral ibuprofen and 42.1?% received oral indomethacin. The overall closure rate of PDA was 60 and 65.7?% in the ibuprofen and indomethacin groups, respectively. Closure rate was significantly higher when the drugs were administered at an early postnatal age (<8?days) (83.3?% [p?=?0.02] in the indomethacin group and 75?% [p?=?0.03] in the ibuprofen group) in neonates >28?weeks (ibuprofen group 66.7?% [p?=?0.02]; indomethacin group 65.5?% [p?=?0.04]) and in babies with birth weight?>1,000?g (ibuprofen group 62.2?%; indomethacin group 70?% [p?=?0.04 in both groups]). Complications were similar in both groups. The efficacy of both drugs was similar. Poor closure in our study could be because of genetic differences in pharmacokinetics of drug metabolism in the Indian population. Regimens with higher doses or increased duration of treatment may increase the frequency of closure. Studies with larger numbers of subjects with evaluation of pharmacokinetic parameters are therefore required.